Related Experiment Video

Updated: May 21, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Effects of olmesartan on arterial stiffness in rats with chronic renal failure

Yao-Chen Chuang1, Ming-Shiou Wu, Yi-Kai Su

  • 1Institute of Physiology, College of Medicine, National Taiwan University, Taipei City, Taiwan. d93441002@ntu.edu.tw

Cardiovascular Diabetology
|June 15, 2012
PubMed
Abstract

Insights

Olmesartan (OLM) treatment improved arterial stiffness and renal function in chronic renal failure (CRF) rats. OLM reduced oxidative stress markers like malondialdehyde (MDA) and advanced glycation end products (AGEs).

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Antioxidant properties of olmesartan (OLM), an angiotensin II type 1 receptor (AT(1)R) blocker, may offer renal protection beyond blood pressure reduction.
  • Chronic renal failure (CRF) is linked to hypertension and renal artery disease, suggesting a role for oxidative stress.

Purpose of the Study:

  • To investigate the correlation between OLM's antioxidative activities and arterial stiffness, reactive oxygen species, and advanced glycation end products (AGEs) in rats with CRF.
  • To assess OLM's impact on hemodynamic parameters, renal function, and oxidative stress markers in CRF rats.

Main Methods:

  • CRF was induced in rats via 5/6 nephrectomy.
  • Rats were randomly assigned to receive OLM (10 mg/day) or a control treatment for 8 weeks.
  • Measurements included hemodynamic states, oxidative stress markers (MDA), AGEs, and renal function (BUN, SCr).

Main Results:

  • OLM treatment abrogated hemodynamic derangements, normalized cardiac output, and reduced mean aortic pressure and total peripheral resistance in CRF rats.
  • OLM improved aortic compliance and wave transit time, indicating reduced arterial stiffness and attenuated left ventricular systolic load.
  • OLM significantly increased BUN and SCr clearance, reduced MDA levels in aorta and serum, and decreased AGEs in the aortic wall.

Conclusions:

  • Olmesartan (OLM) ameliorates arterial stiffness in chronic renal failure (CRF) rats.
  • OLM treatment inhibits malondialdehyde (MDA) and advanced glycation end products (AGEs) levels.
  • The beneficial effects of OLM are attributed to the reduction of oxidative stress in the aortic wall.

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...